Benev­o­len­tAI, Ex­sci­en­tia on the come­back trail af­ter se­cur­ing sep­a­rate AI drug dis­cov­ery deals with Mer­ck KGaA

Mer­ck KGaA has inked two sep­a­rate AI drug dis­cov­ery part­ner­ships with Benev­o­len­tAI and Ex­sci­en­tia that are fo­cused on three tar­gets in on­col­o­gy, neu­rol­o­gy and im­munol­o­gy …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER